Home Site Map Contact Us
  Back to Salix Products
MoviPrep

About MoviPrep



MoviPrep®the well–tolerated, low–volume PEG

This information is intended for U.S. residents only.


MoviPrep is indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age and older. It is a tolerable, low–volume 2–liter PEG with the effectiveness of a high–volume prep. MoviPrep is proven to provide consistent visibility throughout the entire colon.

MoviPrepthe #1–prescribed branded purgative worldwide1

  • 89% of patients achieve good or excellent quality preparations, regardless of age2
  • 9 out of 10 patients would take MoviPrep again for their next procedure1
  • Proven more tolerable than 4–liter preparations, with less nausea, vomiting, and abdominal pains2
  • Contains no bisacodyl or the cramping and frequent patient callbacks that go with it1
  • No differences in safety and tolerability between younger and elderly patients2
  • Osmotically and electrolytically balanced to keep patients hydrated

back to top

First FDA–approved PM/AM Split DosingTM regimen in a PEG product

MoviPrep has a proven PM/AM Split Dosing regimen, which improves quality bowel preparation and colonoscopy. In a clinical trial evaluating PM/AM Split Dosing vs evening–only dosing, the total number of flat lesions detected in patients who received some preparation the same day as the colonoscopy was significantly higher than in those prepared the evening before.3 In another study, 89.3% of bowel preparations were effective when split dosed vs 69.5% for evening–only preparations.4

  • MoviPrepFDA–approved PM/AM Split Dosing regimen since 20062
  • 89% good or excellent overall colon cleansing with a PM/AM Split Dosing regimen2

back to top

References

  1. Data on file. Salix Pharmaceuticals, Inc.
  2. MoviPrep [prescribing information]. Morrisville, NC: Salix Pharmaceuticals, Inc.; 2009.
  3. Parra–Blanco A, Nicolás–Pérez D, Gimeno–García A, et al. The timing of bowel preparation before colonoscopy determines the quality of cleansing, and is a significant factor contributing to the detection of flat lesions: a randomized study. World J Gastroenterol. 2006;12:6161–6166.
  4. Khan MA, Wasiuddin N, Brown M. Patient acceptance, convenience and efficacy of one–day versus two–day colonoscopy bowel preparation. Poster presented at: Digestive Disease Week; May 17–22, 2008; San Diego, CA.

back to top



MoviPrep® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. MoviPrep is contraindicated in patients who have had a severe hypersensitivity reaction to any of its components. MoviPrep should be used with caution in patients using concomitant medications that increase the risk of electrolyte abnormalities, in patients with known or suspected hyponatremia, severe ulcerative colitis, ileus, gastrointestinal obstruction or perforation, gastric retention, toxic colitis, toxic megacolon, or glucose-6-phosphate dehydrogenase deficiency. In clinical trials, abdominal distention, anal discomfort, thirst, nausea, and abdominal pain were the most common adverse reactions to MoviPrep administration. MoviPrep contains a maximum of 2.33 mg of phenylalanine per treatment.

Consult with your physician to see if this product is right for you.

For complete Prescribing Information, please click here.


For product information, adverse event reports, and product complaint reports please call:

Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email:

  • MoviPrep Physician Resource Center
  • MoviPrep Product Prescribing Information

  • MoviPrep Patient Newsletter

Click here here for Patient Instructions